Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC
默克默克(US:MRK) Businesswire·2026-01-07 19:50

公司动态 - 默克公司宣布启动名为KANDLELIT-007的III期临床试验 [1] - 该试验旨在评估研究性口服选择性KRAS G12C抑制剂calderasib与KEYTRUDA QLEX™的联合疗法 [1] - 该联合疗法针对的适应症为KRAS G12C突变、晚期或转移性非鳞状非小细胞肺癌的一线治疗 [1] 产品管线 - 试验药物calderasib的内部研发代码为MK-1084 [1] - 联合用药的另一组成部分KEYTRUDA QLEX™是帕博利珠单抗与透明质酸酶α-fpromph的复方制剂 [1]

Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC - Reportify